CN113166140B - Cdk8/19抑制剂 - Google Patents

Cdk8/19抑制剂 Download PDF

Info

Publication number
CN113166140B
CN113166140B CN201980065665.1A CN201980065665A CN113166140B CN 113166140 B CN113166140 B CN 113166140B CN 201980065665 A CN201980065665 A CN 201980065665A CN 113166140 B CN113166140 B CN 113166140B
Authority
CN
China
Prior art keywords
pyrazol
phenyl
amino
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980065665.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN113166140A (zh
Inventor
A·L·明迪奇
A·J·切斯特诺娃
M·A·卡萨特金纳
A·I·阿拉菲诺夫
A·S·加夫里洛夫
A·A·叶夫多基莫夫
L·V·伦斯密特
E·A·马克西门科
M·S·米希纳
S·A·西洛诺夫
E·J·斯米尔诺夫
P·A·雅科夫列夫
D·V·莫罗佐夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocard Jsc
Original Assignee
Biocard Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocard Jsc filed Critical Biocard Jsc
Publication of CN113166140A publication Critical patent/CN113166140A/zh
Application granted granted Critical
Publication of CN113166140B publication Critical patent/CN113166140B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980065665.1A 2018-08-03 2019-07-31 Cdk8/19抑制剂 Active CN113166140B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2018128415A RU2761824C2 (ru) 2018-08-03 2018-08-03 Ингибиторы CDK8/19
RU2018128415 2018-08-03
PCT/RU2019/050123 WO2020027704A1 (ru) 2018-08-03 2019-07-31 Ингибиторы cdk8/19

Publications (2)

Publication Number Publication Date
CN113166140A CN113166140A (zh) 2021-07-23
CN113166140B true CN113166140B (zh) 2024-06-14

Family

ID=69231230

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980065665.1A Active CN113166140B (zh) 2018-08-03 2019-07-31 Cdk8/19抑制剂

Country Status (19)

Country Link
US (1) US11840531B2 (https=)
EP (1) EP3831829A4 (https=)
JP (1) JP7365396B2 (https=)
KR (1) KR102926889B1 (https=)
CN (1) CN113166140B (https=)
AR (1) AR115898A1 (https=)
AU (1) AU2019313199B2 (https=)
BR (1) BR112021001939A2 (https=)
CA (1) CA3108298A1 (https=)
CL (1) CL2021000282A1 (https=)
CO (1) CO2021001174A2 (https=)
EA (1) EA202190452A1 (https=)
MA (1) MA52375B2 (https=)
MX (1) MX2021001335A (https=)
PE (1) PE20210416A1 (https=)
PH (1) PH12021550258A1 (https=)
RU (1) RU2761824C2 (https=)
TW (1) TWI839374B (https=)
WO (1) WO2020027704A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533016A (ja) 2020-07-11 2023-08-01 ファイザー・インク 抗ウイルス性ヘテロアリールケトン誘導体
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2024109660A1 (zh) * 2022-11-21 2024-05-30 上海齐鲁制药研究中心有限公司 Cdk抑制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106817900A (zh) * 2014-07-17 2017-06-09 默克专利有限公司 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
MX2010006244A (es) * 2007-12-06 2010-12-02 Schering Corp Moduladores de gamma secretasa.
CN103249721B (zh) * 2010-10-18 2016-10-12 拉夸里亚创药株式会社 作为ttx-s阻滞剂的芳胺衍生物
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
EP3383875B1 (en) * 2015-11-30 2022-02-09 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as anticancer agents and the process for the preparation thereof
US11213520B2 (en) * 2016-05-23 2022-01-04 Boehringer Ingelheim International Gmbh Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106817900A (zh) * 2014-07-17 2017-06-09 默克专利有限公司 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途

Also Published As

Publication number Publication date
TW202012406A (zh) 2020-04-01
AU2019313199A1 (en) 2021-03-11
RU2018128415A (ru) 2020-02-04
PE20210416A1 (es) 2021-03-04
CO2021001174A2 (es) 2021-02-26
BR112021001939A2 (pt) 2021-04-27
MX2021001335A (es) 2021-04-12
CN113166140A (zh) 2021-07-23
EP3831829A1 (en) 2021-06-09
CL2021000282A1 (es) 2021-08-13
RU2761824C2 (ru) 2021-12-13
JP7365396B2 (ja) 2023-10-19
AR115898A1 (es) 2021-03-10
AU2019313199B2 (en) 2023-07-06
RU2018128415A3 (https=) 2021-03-30
EA202190452A1 (ru) 2021-04-13
US11840531B2 (en) 2023-12-12
MA52375B2 (fr) 2023-02-28
PH12021550258A1 (en) 2021-10-11
WO2020027704A1 (ru) 2020-02-06
TWI839374B (zh) 2024-04-21
MA52375A1 (fr) 2021-12-31
US20210246138A1 (en) 2021-08-12
KR102926889B1 (ko) 2026-02-19
EP3831829A4 (en) 2022-04-20
CA3108298A1 (en) 2020-02-06
KR20210040416A (ko) 2021-04-13
JP2021533143A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
CN116457358A (zh) 作为ras抑制剂以治疗癌症的吲哚衍生物
JP7365332B2 (ja) Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
TWI702205B (zh) 表皮生長因子受體抑制劑
CN113166140B (zh) Cdk8/19抑制剂
RU2763347C2 (ru) Новые ингибиторы cdk8/19
RU2754441C2 (ru) Новые ингибиторы cdk8/19
HK40058347A (en) Cdk8/19 inhibitors
RU2851298C2 (ru) Новые ингибиторы JAK1-киназ
RU2852021C2 (ru) Новые ингибиторы JAK1-киназ
RU2786524C2 (ru) Ингибиторы рецептора эпидермального фактора роста
HK40058347B (zh) Cdk8/19抑制剂
RU2739489C2 (ru) Новые гетероциклические соединения как ингибиторы CDK8/19
EP4592283A1 (en) Cyclin-dependent kinase 7 inhibitors
BR112020007549A2 (pt) compostos inibidores de pirimidina tbk/ikképsilon e uso dos mesmos
EA042225B1 (ru) Ингибиторы cdk8/19
CA3268634A1 (en) Cyclin-dependent kinase 7 inhibitors
HK40128715A (zh) 细胞周期蛋白依赖性激酶7的抑制剂
TW202120511A (zh) 雜環化合物
HK40036003A (en) Epidermal growth factor receptor inhibitors
BR112020002674B1 (pt) Compostos heterocíclicos como inibidoresde cdk8/19, método para inibir a atividade biológica de quinases de proteína, composição farmacêutica, método para tratamento de uma doença ou distúrbio e uso do composto ou sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058347

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant